Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or OpenAthens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Clinical Study

Clinical Characteristics and Outcomes of Lung Cancer with Pulmonary Embolism

Chuang Y.-M.a · Yu C.-J.b

Author affiliations

Departments of Internal Medicine,aNational Taiwan University Hospital, Yun-Lin branch, Dou-Liou, and bNational Taiwan University Hospital and National Taiwan University Medical College, Taipei, Taiwan, ROC

Related Articles for ""

Oncology 2009;77:100–106

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Clinical Study

Received: May 16, 2008
Accepted: December 30, 2008
Published online: July 21, 2009
Issue release date: August 2008

Number of Print Pages: 7
Number of Figures: 2
Number of Tables: 4

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: https://www.karger.com/OCL

Abstract

Background: Cancer patients have a higher risk for thrombosis that is usually related to advanced stage and poor prognosis. This study aimed to identify the clinical picture and outcome of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) patients with pulmonary embolism (PE). Patients and Methods: From 1996 to 2005, the clinical presentation of lung cancer patients with PE was evaluated. Their survival was compared with matched controls by log-rank test. Results: A total of 24 patients, 17 men (70.8%) and 7 women (median age: 62.5 years), were identified. Nineteen patients (79.2%) initially presented with advanced lung cancer (16 stage IV, 1 stage III-b NSCLC and 2 extensive-stage SCLC). Wells’ clinical prediction score for PE only predicted moderate probability (median: 5.25). In patients with PE, survival was significantly shorter than in matched control patients (243.5 vs. 327 days, p = 0.01). This difference was more significant when PE presented concomitant with cancer (p = 0.003) than when PE developed during cancer treatment (p = 0.206). Conclusions: PE is an important event in lung cancer patients which usually occurs in advanced disease and affects survival. In patients presenting PE at the initial diagnosis of cancer, the prognosis was the worst.

© 2009 S. Karger AG, Basel


References

  1. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG: Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy (review). Chest 2004;126:338S–400S.
  2. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA: Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846–1850.
  3. Goldhaber SZ: Pulmonary embolism. Lancet 2004;363:1295–1305.
  4. Goldhaber SZ, Visani L, De Rosa M: Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999;353:1386–1389.
  5. Ribeiro A, Lindmarker P, Johnsson H, Juhlin-Dannfelt A, Jorfeldt L: Pulmonary embolism: one-year follow-up with echocardiography Doppler and five-year survival analysis. Circulation 1999;99:1325–1330.
  6. Kearon C: Natural history of venous thromboembolism. Circulation 2003;107:I22–I30.
  7. Wells PS, Anderson DR, Rodger M, Ginsberg JS, Kearon C, Gent M, Turpie AG, Bormanis J, Weitz J, Chamberlain M, Bowie D, Barnes D, Hirsh J: Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 2000;83:416–420.
  8. Kelly J, Hunt BJ: A clinical probability assessment and D-dimer measurement should be the initial step in the investigation of suspected venous thromboembolism. Chest 2003;124:1116–1119.
  9. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE: Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:401S–428S.
  10. Wittram C, Maher MM, Yoo AJ, Kalra MK, Shepard JA, McLoud TC: CT angiography of pulmonary embolism: diagnostic criteria and causes of misdiagnosis. Radiographics 2004;24:1219–1238.
  11. Varki A: Trousseau’s syndrome: multiple definitions and multiple mechanisms. Blood 2007;110:1723–1729.
  12. Prandoni P, Falanga A, Piccioli A: Cancer and venous thromboembolism. Lancet Oncol 2005;6:401–410.
  13. Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto S: Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 2007;5:520–527.
  14. Lee AY, Levine MN: Venous thromboembolism and cancer: risks and outcomes. Circulation 2003;107:I17–I21.
  15. Sorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL: Incidence of cancer after primary deep venous thrombosis or pulmonary embolism. Lakartidningen 2000;97:1961–1964.
  16. Tesselaar ME, Osanto S: Risk of venous thromboembolism in lung cancer (review). Curr Opin Pulm Med 2007;13:362–367.
  17. Blom JW, Osanto S, Rosendaal FR: The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost 2004;2:1760–1765.
  18. Kuter DJ: Thrombotic complications of central venous catheters in cancer patients. Oncologist 2004;9:207–216.
  19. Anderson AJ, Krasnow SH, Boyer MW, Cutler DJ, Jones BD, Citron ML, Ortega LG, Cohen MH: Thrombosis: the major Hickman catheter complication in patients with solid tumor. Chest 1989;95:71–75.
  20. Couban S, Goodyear M, Burnell M, Dolan S, Wasi P, Barnes D, Macleod D, Burton E, Andreou P, Anderson DR: Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 2005;23:4063–4069.
  21. Klerk CP, Smorenburg SM, Buller HR: Thrombosis prophylaxis in patient populations with a central venous catheter: a systematic review. Arch Intern Med 2003;163:1913–1921.
  22. Ger LP, Hsu WL, Chen KT, Chen CJ: Risk factors of lung cancer by histological category in Taiwan. Anticancer Res 1993;13:1491–1500.
  23. Stein PD, Terrin ML, Hales CA, Palevsky HI, Saltzman HA, Thompson BT, Weg JG: Clinical, laboratory, roentgenographic, and electrocardiographic findings in patients with acute pulmonary embolism and no pre-existing cardiac or pulmonary disease. Chest 1991;100:598–603.
  24. Unsal E, Atalay F, Atikcan S, Yilmaz A: Prognostic significance of hemostatic parameters in patients with lung cancer. Respir Med 2004;98:93–98.
  25. Lee AY, Julian JA, Levine MN, Weitz JI, Kearon C, Wells PS, Ginsberg JS: Clinical utility of a rapid whole-blood D-dimer assay in patients with cancer who present with suspected acute deep venous thrombosis. Ann Intern Med 1999;131:417–423.
  26. Gomes MP, Deitcher SR: Diagnosis of venous thromboembolic disease in cancer patients. Oncology (Williston Park) 2003;17:126–135, 139; discussion 139–144.
  27. Tilyou S: PIOPED (Prospective Investigation in Pulmonary Embolism Diagnosis) study compares lung scans and pulmonary arteriography. J Nucl Med 1989;30:279–280.
  28. Cohen MH, Makuch R, Johnston-Early A, Ihde DC, Bunn PA Jr, Fossieck BE Jr, Minna JD: Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer. Cancer Treat Rep 1981;65:187–195.
  29. Watine J: Prognostic evaluation of primary non-small cell lung carcinoma patients using biological fluid variables. A systematic review. Scand J Clin Lab Invest 2000;60:259–273.
  30. Tas F, Aydiner A, Demir C, Topuz E: Serum lactate dehydrogenase levels at presentation predict outcome of patients with limited-stage small-cell lung cancer. Am J Clin Oncol 2001;24:376–378.

Article / Publication Details

First-Page Preview
Abstract of Clinical Study

Received: May 16, 2008
Accepted: December 30, 2008
Published online: July 21, 2009
Issue release date: August 2008

Number of Print Pages: 7
Number of Figures: 2
Number of Tables: 4

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: https://www.karger.com/OCL


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.